References

1. World Health Report 2001 - Mental Health: New Understanding, New Hope. World Health Organization: Geneva, Switzerland, 2001.

2. Lieberman, J. F; Greenhouse, J.; Robert, J.; Hamer, M.; Ranga Krishnan, K.; Nemeroff, C. B.; Sheehan, D. V; Thase, M. E.; Martin, B.; Keller, M. B. Neuropsychopharmacology 2005, 30, 445-460.

3. Anderson, I. M.; Nutt, D. J.; Deakin, J. F W J. Psychopharmacol. 2000, 14, 3-20.

4. Goodwin, G. M. J. Psychopharmacol 2003, 17, 149-173.

5. Duffy, F F; Narrow, W; West, J. C.; Fochtmann, L. J.; Kahn, D. A.; Suppes, T; Oldham, J. M.; McIntyre, J. S.; Manderscheid, R. W; Sirovatka, P; Regier, D. et al. Psychiatr. Q. 2005, 76, 213-230.

6. American Psychiatric Association Diagnostic and Statistical Manual of Mental Disorders DSM-IV; APA: Washington, DC, 1994.

7. World Health Organization. The ICD-10 Classification of Mental and Behavioural Disorders: Diagnostic Criteria for Research; World Health Organization: Geneva, Switzerland, 1993.

8. Murray, C. J.; Lopez, A. D. Lancet 1997, 349, 1498-1504.

9. Greenberg, P. E.; Kessler, R. C.; Birnbaum, H. G.; Leong, S. A.; Lowe, S. W.; Berglund, P. A.; Corey-Lisle, P. K. J. Clin. Psychiatr. 2003, 64, 1465-1475.

10. Paykel, E. S. Psychopathology 2002, 35, 94-99.

11. Bieck, P R.; Potter, W Z. Annu. Rev. Pharmacol. Toxicol. 2005, 45, 227-246.

12. Roth, B. L.; Sheffler, D. J.; Kroeze, W K. Nat. Rev Drug Disc. 2004, 3, 353-359.

13. Schildkraut, J. J.; Mooney, J. J. Am. J. Psychiatry 2004, 161, 909-911.

14. Santarelli, L.; Saxe, M.; Gross, C.; Surget, A.; Battaglia, F; Dulawa, S.; Weisstaub, N.; Lee, J.; Duman, R.; Arancio, O. et al. Science 2003, 301, 805-809.

15. Artigas, F; Celada, P.; Laruelle, M.; Adell, A. Trends Pharmacol. Sci. 2001, 22, 224-228.

17. Tellioglu, T; Robertson, D. Expert Rev. Mol. Med. 2001, 19, 1-10.

18. Zill, P; Engel, R.; Baghai, T C.; Juckel, G.; Frodl, T; Muller-Siecheneder, F; Zwanzger, P.; Schule, C.; Minov, C.; Behrens, S. et al. Neuropsychopharmacology 2002, 26, 489-493.

19. Hadley, D.; Hoff, M.; Holik, J.; Reimherr, F; Wender, P.; Coon, H.; Byerley, W Hum. Hered. 1995, 45, 165-168.

20. Lin, Z.; Uhl, G. R. Pharmacogenomics J. 2003, 3, 159-168.

21. McCauley, J. L.; Olson, L. M.; Dowd, M.; Amin, T; Steele, A.; Blakely, R. D.; Folstein, S. E.; Haines, J. L.; Sutcliffe, J. S. Am. J. Med. Genet. Part B (Neuropsychiatric Genetics) 2004, 127, 104-112.

22. NIMH. Bipolar Disorder Research at the National Institute of Mental Health. NIH publication number 00-4502, 2000.

23. Malt, U. F; Robak, O. H.; Madsbu, H. P; Loeb, B. M. Br. Med. J. 1999, 318, 1180-1184.

24. Willner, P Behavioural Models in Psychopharmacology - Theoretical, Industrial and Clinical Perspectives. Oxford University Press: Oxford, UK, 1991.

25. Wong, M.-L.; Licino, J. Nat. Rev Drug Disc. 2005, 3, 136-151.

26. Anisman, H.; Matheson, K Neurosci. Biobehav. Rev. 2005, 29, 525-546.

27. Frazer, A.; Morilak, D. A. Neurosci. Biobehav Rev 2005, 29, 515-523.

28. Dunn, D. A.; Pinkert, C. A.; Kooyman, D. L. Drug Disc. Today 2005, 10, 757-767.

29. Matthews, K.; Christmas, D.; Swan, J.; Sorrell, E Neurosci. Biobehav. Rev. 2005, 29, 503-513.

30. Encinas, J. M.; Vaahtokari, A.; Enikolopov, G. Proc. Nat. Acad. Sci. USA 2006, 103, 8233-8238.

31. Thakker, D. R.; Natt, F; Husken, D.; van der Putten, H.; Maier, R.; Hoyer, D.; Cryan, J. F Mol. Psychiatry 2005, 10, 714.

32. Khan, A.; Khan, S. R.; Walens, G.; Kolts, R.; Giller, E. L. Neuropsychopharmacology 2003, 28, 552-557.

33. Thase, M. E. J. Clin. Psychiatry 1999, 60, 3-9, discussion 31-35.

34. Fava, M.; Rush, A. J.; Trivedi, M. H.; Nierenberg, A. A.; Thase, M. E.; Sackeim, H. A.; Quitkin, F M.; Wisniewski, S.; Lavori, P. W; Rosenbaum, J. F; Kupfer, D. J. Psychiatr. Clin. North Am. 2003, 26, 457-494.

35. Barbui, C.; Hotopf, M. Acta Psychiatr. Scand. 2001, 104, 92-95.

36. Licinio, J.; Wong, M.-L. Rev. Drug Disc. 2005, 4, 165-171.

38. Millan, M. J. Eur. J. Pharmacol. 2004, 500, 371-384.

39. Burger's Medicinal Chemistry and Drug Discovery. In: Nervous System Agents, 6th Ed.; Abraham, D. J., Ed.; J. Wiley & Sons, Inc., 2003; Vol 6, p. 500.

40. Owens, M. J.; Knight, D. L.; Nemeroff, C. B. Biol. Psychiatry 2001, 50, 345-350.

41. Youdim, M. B. H.; Bakhle, YS. British. J. Pharmacol. 2006, S287-S296.

42. Wong, D. T; Perry, K. W; Bymaster, F P Nat. Rev. Drug Disc. 2005, 4, 764-774.

43. Shifman, S.; Bronstein, M.; Sternfeld, M.; Pisante A.; Weizman, A.; Reznik, I.; Spivak, B.; Grisaru, N.; Karp, L.; Schiffer, R.; Kotler, M.; Strous, R. D.; Swartz-Vanetik, M.; Knobler H. Y; Shinar, E. et al. Am. J. Med. Genet. 2004, 128B, 61-64.

44. Manji, H. K.; Moore, G. J.; Rajkowska, G.; Chen, G. Mol. Psychiatry 2000, 5, 578-593.

45. Keck, P. E., Jr.; McElroy, S. L.; Arnold, L. M. Med. Clin. North Am. 2001, 85, 645-661.

46. Brandish, P E.; Su, M.; Holder, D. J.; Hodor, P.; Szumiloski, J.; Kleinhanz, R. R.; Forbes, J. E.; McWhorter, M. E.; Duenwald, S. J.; Parrish, M. L. et al. Neuron 2005, 25, 861-872.

47. Compton, M. T.; Nemeroff, C. B. Clin. J Psychiatry 2000, 61, 57-67.

48. Licht, R. W Acta Psychiatr. Scand. 1998, 97, 387-397.

49. Bowden, C. L.; Asnis, G. M.; Ginsberg, L. D.; Bentley, B.; Leadbetter, R.; White, R. Drug Safety 2004, 27, 173-184.

50. Berk, M.; Segal, J.; Janet, L.; Vorster, M. Drugs 2001, 61, 1407-1414.

51. Delgado, P L.; Miller, H. L.; Salomon, R. M.; Licinio, J.; Heninger, G. R.; Gelenberg, A. J.; Charney, D. S. Psychopharmacol. Bull. 1993, 29, 389-396.

52. Preskorn, S. H. J. Clin. Psychiatry 1995, 56, 12-21.

54. Whale, R.; Clifford, E. M.; Bhagwagar, Z.; Cowan, P J. Br. J. Psychiatr 2001, 178, 454-457.

55. Wood, M. D.; Reavill, C.; Trail, B.; Wilson, A.; Stean, T.; Kennett, G. A.; Lightowler, S.; Blackburn, T P.; Thomas, D.; Gager, T L. et al. Neuropharmacology 2001, 41, 186-199.

56. Millan, M. J.; Gobert, A.; Lejeune, F; Dekeyne, A.; Newman-Tancredi, A.; Pasteau, V; Rivet, J.-M.; Cussac, D. JPET 2003, 306, 954-964.

57. Holmes, A.; Heilig, M.; Rupniak, N. M. J.; Steckler, T; Griebel, G. Trends Pharmacol. Sci. 2003, 24, 580-595.

58. Todorovic, C.; Jahn, O.; Tezval, H.; Hippel, C.; Spiess, J. J. Neurosci. Biobehav. Rev. 2005, 29, 1323-1333.

59. Borowsky, B.; Durkin, M. M.; Ogozalek, K.; Marzabadi, M. R.; DeLeon, J.; Lagu, B.; Heurich, R.; Lichtblau, H.; Shaposhnik, Z.; Daniewska, I. et al. Nat. Med. 2002, 8, 779-781.

60. Brewer, A.; Echevarria, D. J.; Langel, U.; Robinson, J. K. Neuropeptides 2005, 39, 323-326.

61. Blackburn, T. P.; Swanson, C. J.; Wolinsky, T. D.; Konkel, M. J.; Walker, M. M.; Durkin, M.; Artymyshyn, R. P; Smith, K. E.; Jones, K. J.; Craig, D. A. et al. Neuropsychopharmacology 2005, 30, S99.

62. Cosford, N. D.; Tehrani, L.; Roppe, J.; Schweiger, E.; Smith, N. D.; Anderson, J.; Bristow, L.; Brodkin, J.; Jiang, X.; McDonald, I. et al. J. Med. Chem. 2003, 46, 204-206.

63. Skolnick, P. Eur. J. Pharmacol. 1999, 375, 31-40.

64. Zarate, C. A.; Singh, J. B.; Carlson, P. J.; Brutsche, M. E.; Ameli, R.; Luckenbaugh, D. A.; Charney, D. S.; Manji, H. K. Arch. Gen. Psychiatry 2006, 63, 856-864.

65. Schoepp, D. D.; Wright, R. A.; Levine, L. R.; Gaydos, B.; Potter, W Z. Stress 2003, 6, 189-197.

66. Spooren, W; Gasparini, F Drug News Perspect. 2004, 17, 251-257.

67. Grillon, C.; Cordova, J.; Levine, L. R.; Morgan, C. A. Psychopharmacology (Berl.) 2003, 168, 446-454.

68. Marek, G. J.; Wright, R. A.; Gewirtz, J. C.; Schoepp, D. D. Neuroscience 2001, 105, 379-392.

69. Moldrich, R. X.; Beart, P. M. Curr. Drug Targets CNS Neurol. Disord. 2003, 2, 109-122.

70. Cryan, J. F; Kaupmann, K. Trends Pharmacol. Sci. 2005, 26, 36-43.

71. Flores, B. H.; Kenna, H.; Keller, J.; Solvason, H. B.; Schatzberg, A. F Neuropsychopharmacology 2006, 3, 628-636.

72. Grillon, C.; Cordova, J.; Levine, L. R.; Morgan, C. A. Psychopharmacology (Berl.) 2003, 168, 446-454.

73. Young, A. H.; Gallagher, P.; Watson, S.; Del-Estal, D.; Owen, B. M. and Ferrier, I. N. Neuropsychopharmacology 2004, 29, 1538-1545.

74. O'Donnell, J. M.; Zhang, H.-T. Trends Pharmacol. Sci. 2004, 25, 158-163.

75. Branchek, T. A.; Blackburn, T. P Curr. Opin. Pharmacol. 2003, 3, 90-97.

76. Lindermann, L.; Hoener, M. Trends Pharmacol. Sci. 2005, 26, 5, 274-280.

77. Datamonitor Strategic Perspectives 2001: Antidepressants DMHC1695. Datamonitor: New York, 2001.

Biographies

Thomas P Blackburn, DSc, FBPhS, is an internationally recognized neuroscientist whose industry experience embraces both major pharmaceutical and biotech companies. He received his graduate degree from Manchester University, England. His expertise lies in neuropharmacology and clinical drug development, and he was responsible for the preclinical and clinical development of several compounds, including Paxil. He has published over 100 papers in the field of neuroscience and he is a co-inventor on several patents. He is a Past President of the British Pharmacological Society and a nonexecutive board member for Motac Neuroscience Ltd.

Jan Wasley has a scientific background in organic and medical chemistry. He received his BSc and PhD at the University of Nottingham, England. Dr Wasley held positions of increasing responsibility within the Research Department of Ciba-Geigy in drug discovery and drug development activities. He joined Neurogen Corporation in 1993 as Director of Chemistry and became involved in the development of Neurogen's Accelerated Intelligent Drug Design (AIDD) technologies. He retired from Neurogen in 2001.

© 2007 Elsevier Ltd. All Rights Reserved Comprehensive Medicinal Chemistry II

No part of this publication may be reproduced, stored in any retrieval system or transmitted ISBN (set): 0-08-044513-6 in any form by any means electronic, electrostatic, magnetic tape, mechanical, photocopying, recording or otherwise, without permission in writing from the publishers ISBN (Volume 6) 0-08-044519-5; pp. 45-83

Beat Depression Now

Beat Depression Now

Let me be up front. My intention is to sell you something. Normally, it's not wise to come out and say that. However, I can do so because I have such an incredible deal for you that you'd be crazy to pass on it.

Get My Free Ebook


Post a comment